About: Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Status: Delisted — removed_from_provider. This asset is no longer trading; historical data is shown.
AVDLNASDAQAvadel Pharmaceuticals PLC
Avadel Pharmaceuticals PLC share price
AVDL price activity
Last Price
Change (24hr)
USD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
AVDL price performance
AVDL Market Signals